

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 0818 – May 2018

**Icatibant acetate (Firazyr®) 30 mg solution for injection in
pre-filled syringe**

Limited submission by Shire Pharmaceuticals

Recommendation of AWMSG

Icatibant acetate (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that icatibant acetate (Firazyr®) satisfied the AWMSG criteria for ultra-orphan status.
- This advice incorporates and replaces the existing AWMSG recommendation on icatibant acetate (Firazyr®) for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency) (Advice number 0512, originally published March 2012).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3293), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	May 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0818:
Icatibant acetate (Firazyr®) 30 mg solution for injection in pre-filled syringe. May 2018.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>